APOA1: a Protein with Multiple Therapeutic Functions

Curr Atheroscler Rep. 2021 Feb 16;23(3):11. doi: 10.1007/s11883-021-00906-7.


Purpose of the review: Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states.

Recent findings: Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.

Keywords: APOA1; Atherosclerosis; Cancer; Diabetes; Neurological disorders; Thrombosis.

Publication types

  • Review

MeSH terms

  • Apolipoprotein A-I
  • Atherosclerosis* / drug therapy
  • Humans
  • Lipoproteins, HDL
  • Neoplasms*


  • APOA1 protein, human
  • Apolipoprotein A-I
  • Lipoproteins, HDL